Navigation Links
Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Date:12/3/2010

SEATTLE, Dec. 3, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application ("NDA") to treat relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL"). CTI had requested accelerated approval of its pixantrone NDA for a patient group for which there are no drugs currently approved in this clinical setting. The Office of Oncology Drug Products issued a Complete Response Letter to CTI related to this NDA stating, in part, that CTI's prior clinical trial, PIX301, did not demonstrate efficacy, and that CTI should conduct an additional clinical trial prior to approval. Although CTI is preparing to initiate its PIX306 trial, which would serve as either a post-approval confirmatory trial or a second registration trial for approval, CTI has filed an appeal under the FDA's formal dispute resolution process asking the Office of New Drugs to conclude that PIX301 demonstrated efficacy.

"We believe the FDA diverged from accepted statistical principles and practices when the FDA applied a more stringent statistical significance level in concluding that the PIX301 primary analysis required an adjustment for type 1 error as if an interim analysis had been conducted. This was not the case in the PIX301 trial where only a single final analysis was undertaken," said Richard Kay, PhD, Statistical Consultant, RK Statistics Ltd., Honorary Visiting Professor, School of Pharmacy, Cardiff University. "We believe the results of the PIX301 clinical trial should be analyzed with the appropriate threshold that is standard for trials of this type in which only one efficacy analysis was conducted."

FDA regulations provide a formal dispute resolution process to obtain review of any FDA decision, including a
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
(Date:8/28/2015)... 28, 2015  With the heroin epidemic in ... Jacksonville -based Lakeview Health drug and ... helping to explain why fentanyl is causing a new ... 50 times more potent than pharmaceutical grade heroin and ... the risk of death skyrockets. "Fentanyl can ...
(Date:8/28/2015)... 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical company ... announced the filing of a registration statement on Form ... relating to a proposed initial public offering of its ... and the price range for the offering have not ... stock under the symbol "CTMX" on the NASDAQ Global ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... presented at 12th Congress of European Hematology ... -- Alexion,Pharmaceuticals, Inc. today announced results from ... (eculizumab) for the,treatment of paroxysmal nocturnal hemoglobinuria ... organized by The European,Hematology Association (EHA) in ...
... over Placebo Larger at One Year than at ... 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the,benefits ... 2 study in mild-to- moderate Alzheimer's,disease were statistically ... Importantly, on every endpoint studied, the benefits,of Dimebon ...
Cached Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6
(Date:8/31/2015)... TX (PRWEB) , ... August 31, 2015 , ... ... EARLIER Awareness campaign, TAKE ACTION. NOT CHANCES. (SM) will be featured on a ... The eye-catching campaign image is designed to inspire and promote earlier awareness of ...
(Date:8/31/2015)... Ann Arbor, Michigan (PRWEB) , ... August 31, ... ... writes standards, and tests and certifies products for the water, food, health sciences ... as complying with NSF/ANSI 61 for their advanced iron filtration media, Pro-OX Manganese ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... ... 30, 2015 , ... ProTrailer Party is a new and exciting set of ... styled and detailed presets, allowing FCPX users to immerse the audience into the party. ... film makers save time while adding professional titles to every project. , ProTrailer Party ...
(Date:8/30/2015)... ... ... Negotiating an FDA Import Hold Crisis:, Strategies for Challenging FDA Findings, **FDAnews ... , US authorities are holding imports more than ever before, particularly at ports that ... an uptick and a new final rule, having a top-notch import compliance program is ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3
... for,Protective Coatings is pleased to announce that the ... of certification credits,for industrial hygienists who pass the ... Refresher (C-5) training courses. ABIH is a non-profit,professional ... of industrial hygiene and is the certifying organization ...
... House Science and Technology Committee for Holding Health IT ... ... IT Now!,Coalition, co-chaired by former Sen. John Breaux and former Rep. Nancy,Johnson, ... session. "It,s time for Congress to act so that our health ...
... ) announced today the final tabulation of votes at its,Annual Meeting ... -- Shareholders voted to adopt the merger agreement with ... to approve the merger agreement. Approval ... vote of a majority of shares voting on this ...
... SEIU United Healthcare,Workers-West and SEIU Local ... stop Tenet Healthcare Corp. from cutting health ... registered nurses,pharmacists, licensed vocational nurses, respiratory care ... Workers represented by the two unions ...
... Ramps ... Million, CHICAGO, Sept. 26 Since its launch in April, more ... and have lost more than three-quarters of a million pounds.,Challenge founder Dr. ... will lead the way to a million pounds lost by the,final stop ...
... tension, ... avoid tissue damage, ANDOVER, Mass., Sept. 26 Smith ... launch of the,KINSA RC 5.5 Suture Anchor, designed to provide secure repair ... of muscles,and tendons that control shoulder motion. Surgeons can repair these ...
Cached Medicine News:Health News:ABIH Approves Certification Credit for SSPC Training Courses 2Health News:Health IT Now! Coalition Calls on Congress to Pass Health Information Technology Legislation This Year 2Health News:Arrow International Announces Annual Meeting Voting Results 2Health News:Unions File Charges Against Tenet Healthcare Corporation 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 2Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 4
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: